Gritstone Oncology Inc (NASDAQ:GRTS) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $20.70 and last traded at $20.22, with a volume of 1783 shares traded. The stock had previously closed at $19.17.
GRTS has been the topic of several recent analyst reports. BTIG Research initiated coverage on shares of Gritstone Oncology in a research note on Tuesday, October 23rd. They set a “buy” rating and a $26.00 target price on the stock. Goldman Sachs Group assumed coverage on shares of Gritstone Oncology in a research note on Tuesday, October 23rd. They issued a “neutral” rating and a $18.00 price target on the stock. Barclays assumed coverage on shares of Gritstone Oncology in a research note on Tuesday, October 23rd. They issued an “overweight” rating and a $25.00 price target on the stock. Finally, Cowen assumed coverage on shares of Gritstone Oncology in a research note on Tuesday, October 23rd. They issued an “outperform” rating on the stock.
In related news, Director Nicholas Simon purchased 333,333 shares of the firm’s stock in a transaction that occurred on Friday, September 28th. The shares were purchased at an average cost of $15.00 per share, with a total value of $4,999,995.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link.
TRADEMARK VIOLATION WARNING: This news story was reported by Week Herald and is the sole property of of Week Herald. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://weekherald.com/2018/11/07/gritstone-oncology-grts-hits-new-52-week-high-at-20-70.html.
About Gritstone Oncology (NASDAQ:GRTS)
Gritstone Oncology Inc is engaged in the discovery and development of cancer immunotherapies. The company focuses on developing tumor-specific neo-antigens-based therapies for non-small cell lung cancer. Gritstone Oncology Inc has a strategic collaboration with bluebird bio, Inc The company was incorporated in 2015 and is based in San Francisco, California with operations in Cambridge, Massachusetts.
See Also: How to calculate compound interest
Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.